UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' INVESTMENT - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024		Sep. 30, 2023
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period	$ 2,400,299,527	$ 2,195,949,326	$ 2,312,517,069	[1]	$ 2,065,792,821
Issuance of common stock from stock plan transactions (in shares)			1,800,000
Issuance of common stock from stock plan transactions	3,782,044	10,422,050	$ 24,024,353		24,304,861
Issuance of common stock related to acquisitions					0
Repurchases of common stock (in shares)			(5,800,000)
Repurchases of common stock	(96,339,949)	(25,169,378)	$ (187,678,611)		(78,735,501)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock	9,540,105	10,948,031	30,936,895		29,212,236
Dividends declared	(27,293,155)	(27,991,662)	(82,663,756)		(84,049,880)
Net income	122,549,041	104,725,412	316,820,194		311,459,076
Other comprehensive income (loss)	5,089,729	(429,972)	3,671,198		470,194
Balance at end of period	$ 2,417,627,342	$ 2,268,453,807	$ 2,417,627,342		$ 2,268,453,807
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period (in shares)	230,229,539	233,429,994	231,455,443		234,169,335
Balance at beginning of period	$ 13,813,772	$ 14,005,799	$ 13,887,326		$ 14,050,160
Issuance of common stock from stock plan transactions (in shares)	408,566	605,637	1,786,232		1,833,596
Issuance of common stock from stock plan transactions	$ 24,514	$ 36,338	$ 107,174		$ 110,016
Repurchases of common stock (in shares)	(3,194,815)	(776,488)	(5,798,385)		(2,743,788)
Repurchases of common stock	$ (191,689)	$ (46,589)	$ (347,903)		$ (164,628)
Balance at end of period (in shares)	227,443,290	233,259,143	227,443,290		233,259,143
Balance at end of period	$ 13,646,597	$ 13,995,548	$ 13,646,597		$ 13,995,548
Additional  Paid-In Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period	1,000,014,813	942,660,764	968,245,875		917,499,323
Issuance of common stock from stock plan transactions	3,757,530	10,385,712	23,917,179		24,194,845
Repurchases of common stock	(12,363,936)	(2,795,358)	(22,151,437)		(9,707,255)
Stock-based compensation expense related to stock options, employee stock purchases and restricted stock	9,540,105	10,948,031	30,936,895		29,212,236
Balance at end of period	1,000,948,512	961,199,149	1,000,948,512		961,199,149
Retained  Earnings
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period	1,394,446,595	1,252,525,531	1,336,940,990		1,148,386,272
Repurchases of common stock	(83,784,324)	(22,327,431)	(165,179,271)		(68,863,618)
Dividends declared	(27,293,155)	(27,991,662)	(82,663,756)		(84,049,880)
Net income	122,549,041	104,725,412	316,820,194		311,459,076
Balance at end of period	1,405,918,157	1,306,931,850	1,405,918,157		1,306,931,850
Accumulated  Other Comprehensive Income (Loss)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance at beginning of period	(7,975,653)	(13,242,768)	(6,557,122)		(14,142,934)
Other comprehensive income (loss)	5,089,729	(429,972)	3,671,198		470,194
Balance at end of period	$ (2,885,924)	$ (13,672,740)	$ (2,885,924)		$ (13,672,740)

[1] The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.